BioNexus Gene Lab (BGLC)
Distributor of composite-industry chemicals with Malaysian genomic screening and an ASEAN cancer-testing license.
Something off on this page? Send us feedback.
Sells composite-industry chemicals to Southeast Asian manufacturers while operating a smaller Malaysian RNA-screening laboratory and licensing an oncology minimal-residual-disease platform for ASEAN. Chemical trading supplies most revenue, making the company a holding structure rather than a pure-play biotechnology business.
Combines a Malaysian industrial-chemical distributor with a smaller RNA-based screening laboratory and an ASEAN license for an oncology minimal-residual-disease platform. Chemrex buys and resells composite-industry inputs—including resins, fiberglass, adhesives, catalysts and pigments—to Southeast Asian manufacturers, fabricators and contractors. MRNA Scientific analyzes provider-collected blood samples and sends RNA-expression risk reports to referring healthcare providers.
Generates most revenue through chemical trading, with Malaysia its principal market. The licensed VitaGuard platform is intended for cancer residual-disease detection and monitoring after treatment, but reported revenue has so far come from chemical sales and legacy screening. Chemical results depend on supplier availability, working relationships and local demand; laboratory activity relies on sample quality, privacy, quality controls and changing healthcare and laboratory rules. The VitaGuard rollout depends on testing capacity, local regulatory treatment and partner cooperation across ASEAN.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.5M · Total debt $198.6K · Total assets $8.7M · Shareholders' equity $7.8M
- Revenue
- $76.2K
- Operating income
- −$282.4K
- Net income
- −$286.5K
No dividends on record.
| Institutions | 0.60% | 14.4K shares | |
|---|---|---|---|
| 3 holders · as of Jun 30, 2026 | |||
| Insiders | 21.40% | 517.4K shares | |
| 5 holders · as of Aug 14, 2026 | |||
| Strategic holders | 16.23% | 392.3K shares | |
| 1 holder · as of Aug 7, 2026 | |||
| Other | 61.77% | 1.49M shares | |
| remainder | |||
2.42M company shares as of Aug 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Fidelion Diagnostics Pte. Ltd.Strategicother: Greater than 5% holder | 16.23% | 392,329 | filed Aug 7, 2026 |
Lee Su-Leng TanInsiderdirector, 10 percent owner, officer: Chief Executive Officer | 14.01% | 338,709 | filed Aug 14, 2026 |
Set Fui ChongInsiderofficer: Chief Financial Officer | 4.00% | 96,774 | filed Aug 14, 2026 |
Abdul Hamid Muhammad Azrul BinInsiderdirector | 1.33% | 32,258 | filed Aug 14, 2026 |
Chee Keong YapInsiderdirector | 1.33% | 32,258 | filed Aug 14, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Natera
Established tumor-informed ctDNA platform for cancer MRD monitoring.
- Guardant Health
Tissue-free liquid-biopsy MRD test for solid-tumor recurrence monitoring.
- Personalis
Tumor-informed MRD testing for treatment response and recurrence tracking.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BioNexus Gene Lab | $1.51 | +3.42% | $3.5M | — | — | 1.1 | −96.6% |
| Natera | $389.84 | −0.27% | $55.98B | — | — | 20.7 | +37.7% |
| Guardant Health | $176.91 | −0.14% | $23.77B | — | — | 20.1 | +44.3% |
| Personalis | $16.16 | −1.25% | $1.75B | — | — | 25.1 | +30.0% |
| Median | — | — | 20.7 | +37.7% |